Pictet Asset Management Holding SA Sells 38,136 Shares of Pfizer Inc. $PFE

Pictet Asset Management Holding SA cut its stake in Pfizer Inc. (NYSE:PFE) by 1.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,713,383 shares of the biopharmaceutical company’s stock after selling 38,136 shares during the period. Pictet Asset Management Holding SA’s holdings in Pfizer were worth $76,187,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Horizon Financial Services LLC increased its position in shares of Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership bought a new stake in Pfizer during the fourth quarter valued at $28,000. HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE opened at $24.39 on Tuesday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a market cap of $139.04 billion, a PE ratio of 18.62 and a beta of 0.34. The stock has a 50-day moving average of $25.88 and a 200-day moving average of $26.28. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the business earned $0.92 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent’s GLP-1 drugs reportedly cleared a preliminary China insurance review, which could improve the commercial outlook for Ecnoglutide if it is eventually added to the country’s basic medical insurance catalogue. Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and dividend stock, with bullish arguments pointing to its lower forward valuation and income appeal, which may be helping sentiment around the shares. Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
• Positive Sentiment: Pfizer is also being highlighted as one of several reliable dividend names in a volatile market, reinforcing the stock’s defensive-income profile for investors. 3 No-Brainer Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer signed a SuperHuman platform license agreement with Distributed Bio, which is a strategic R&D move but not yet a clear near-term earnings driver. Wired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed Bio
• Negative Sentiment: Recent coverage also continues to weigh on sentiment, noting a CFO departure and a late-stage clinical miss in Pfizer’s oncology pipeline, which reinforces concerns about execution and growth prospects. Read More.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on PFE shares. Citigroup boosted their price objective on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Guggenheim increased their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Finally, CICC Research began coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.